The radioligand binding characteristics of '251-R-( -)4-iodo-2,5dimethoxyphenylisopropylamine
The radioligand binding characteristics of '251-R-( -)4-iodo-2,5dimethoxyphenylisopropylamine
[Y-R-( -)DOI] and 3H-ketanserin were compared in rat and bovine cortical membranes. In rat cortex, '251-R-(-)DOI labels a relatively low density of binding sites (B,,,,, = 2.5 & 0.2 pmol/gm tissue) with high affinity (/CD = 0.63 & 0.09 nh!). In bovine cortex, specific binding of 'a51-R-(-)DOI represents less than 20% of total binding at radioligand concentrations above 0.6 nM, and, therefore, the data cannot be analyzed adequately by Scatchard transformation. By contrast, 3H-ketanserin displays saturable, specific high-affinity binding in both rat cortex (/CD = 1 .O -t 0.1 nM; B,,, = 11 * 0.4 pmol/gm tissue) and bovine cortex (KD = 1.2 + 0.2 nu; B,,,,, = 5.3 + 0.4 pmol/gm tissue).
K, values for 30 drugs were determined for 125l-R-( -)DOIlabeled sites in rat cortex and 3H-ketanserin-labeled sites in bovine cortex. L-Hydroxytryptamine (5-HT) displays 250-fold higher selectivity for the 1251-R-(-)DOI-labeled sites (Ki = 3.0 ? 0.7 nM) than for the 3H-ketanserin-labeled sites (K, = 750 ? 50 nM). Structural congeners of R-(-)DOI display 80-to 160-fold higher affinity for the 'V-R-( -)DOI binding site than for the 3H-ketanserin-labeled binding site. d-LSD and putative 5- HT, antagonists are approximately equipotent at both sites. Significant correlations were found between drug affinities for r251-R-(-)DOI-labeled sites in rat cortex and putative 5-HT,, sites labeled previously by "Br-R-( -)DOB (r = 0.93, p < O.Ol), putative 5-HT,, sites labeled by 3H-ketanserin in bovine cortex (r= 0.63, p < O.Ol), and 5-HT,, binding sites that have been characterized by other investigators (r= 0.78, p < 0.01). No significant correlations were found between drug affinities for 125l-R-( -)DOI-labeled sites in rat cortex and 5-HT,,, 5-HT,,, 5-HT,,, or 5-HT, sites, as determined by previous investigators.
We conclude that Y-R-( -)DOI labels a novel 5-HT binding site subtype (tentatively designated the 5HT,, binding site) that is present in rat cortex but is either absent or minimally present in bovine cortex. By contrast, 3H-ketanserin labels both the putative 5-HT,, site in rat cortex as well as a separate, distinct recognition site that is present in both rat and bovine cortex, tentatively designated the 5-HT,, site.
Received Jan. 3, 1989; revised Mar. 20, 1989; accepted Mar. 28, 1989. We thank Debra Bell for her assistance in the preparation of the manuscript. We thank Anne Hamik for excellent technical assistance. This work was supported in part by the M&night Foundation, the Alfred P. Although 5hydroxytryptamine (5HT) has been recognized as a neurotransmitter in the CNS for over 35 years, its physiological roles remain poorly understood. 5-HT appears to play a significant role in a number of human activities such as sleep, appetite, and sexual function (Fuller, 1984; Glennon, 1988; Peroutka, 1988) . 5-HT has also been implicated in numerous pathological conditions, including depression (Ogren et al., 1979) , migraine (Fozard, 1985; Peroutka, 1988 ) and Alzheimer's disease (Cross et al., 1984) although a specific pathophysiological dysfunction involving 5-HT has yet to be identified. Conceivably, this failure to identify a clear pathophysiological role for 5-HT relates to the fact that multiple 5-HT receptors exist in the CNS.
The 5-HT, receptor was first characterized on the basis of its high affinity for a variety of pharmacological antagonists in radioligand binding assays (Leysen et al., 1978; Peroutka and Snyder, 1979; Peroutka et al., 1981; Hoyer et al., 1985; Peroutka, 1988 ). In the CNS, 5-HT, antagonists selectively block a slow depolarization induced by 5-HT in both facial motor neurons (McCall and Aghajanian, 1980) and cortical pyramidal neurons (Davies et al., 1987) . 5-HT, receptors also appear to modulate specific 5-HT-induced behavioral responses such as the "head twitch" component of the 5-HT behavioral syndrome and blockade of tryptamine-induced seizures (Leysen et al., 1978 (Leysen et al., , 1984 Peroutka et al., 198 1) . The discriminative stimulus properties of 5-HT agonists, including a number of hallucinogens, are potently and selectively blocked by 5-HT, antagonists (Glennon et al., , 1986a . Acute or chronic treatment with various antidepressants, 5-HT agonists and antagonists, 5-HT uptake blockers, and hallucinogens down-regulates 5-HT, receptors while having relatively little effect on the 5-HT, class ofreceptors (Savage et al., 1979; Segawa et al., 1979; Blackshear et al., 1986; Buckholtz et al., 1988; McKenna et al., 1989b) . Peripherally, 5-HT, receptors appear to mediate 5-HT-induced contractions in a number of vascular tissues (Peroutka, 1984) guinea pig ileum (Engel et al., 1984) and tracheal and bronchial smooth muscle (Leysen et al., 1984) . 5-HT, receptors may also mediate regulation of aldosterone production (Matsuoka et al., 1985) and 5-HT-induced platelet aggregation (DeClerck et al., 1983) .
Phenylalkylamines such as 4-bromo-2,5-dimethoxyphenylisopropylamine (DOB) and 4-iodo-2,5-dimethoxyphenylisopropylamine (DOI) represent a class of agents that interact potently with 5-HT, receptors Glennon et al., 1986b) . These agents are also potent hallucinogens in humans (Shulgin, 1978) . As radioligands, these agents have been hypothesized to label a subset of 5-HT, receptors in the CNS (Titeler et al., 1985 Lyon et al., 1987; Glennon et al., 1988) . For example, (+)3H-DOB has been suggested to label a high-affinity "state" of the 5-HT, receptor (Titeler et al., 1985; Lyon et al., 1987) . lZ5-I-DO1 is another phenylalkylamine radioligand that has been analyzed in both autoradiographic McKenna et al., , 1989a ) and homogenate binding studies (Johnson et al., 1987; Glennon et al., 1988) and has also been suggested to label a high-affinity state ofthe 5-HT, recognition site. Initially, our laboratory used "Br-R-( -)DOB Wang et al., 1988) to label a high-affinity phenylalkylamine recognition site. We have suggested that radioligands such as "Br-R-(-)DOB and (+)jH-DOB label a distinct subtype, as opposed to state, of the 5-HT, receptor, tentatively designated the 5-HT,, recognition site (Pierce and Peroutka, 1989) . Since an extensive characterization of 1251-DOI binding in brain homogenates has not yet been reported, we conducted a detailed comparison of the radioligand binding properties of 12SI-R-(-)DOI with the 5-HT, antagonist 'H-ketanserin.
Materials and Methods
Radioligand binding assays were performed according to the methods of Peroutka ( 1986) . Briefly, frozen rat brains or portions of bovine brain, obtained originally from frontal-parietal regions of fresh bovine brains, were thawed from -70°C and cortical tissue was dissected. Tissues were homogenized in 20 vol of 50 mM Tris-HCI (pH 7.7, 25°C) and centrifuged at 45,000 x g for 10 min. The pellet was resuspended in TrisHCl buffer and incubated for IO min at 37°C. After a second centrifugation, the pellet was resuspended in 80 vol of a buffer consisting of 50 mM Tris-HCI, 4 mM calcium chloride, 0.1% ascorbate, and 10m5 M pargyline. The homogenates were immediately used in the binding assay.
Assays consisted of 0.1 ml of a solution of IZSl-R-( -)DOI or 0.1 ml of a solution of 'H-ketanserin (New England Nuclear), 0.8 ml of tissue suspension, and 0.1 ml of buffer or displacing drug. Specific activities of the radioligands were 1800 Ci/mmol for '2SI-R-(-)DOI (corrected for decay on the day of the experiment) and 61.8 Ci/mmol for 'Hketanserin. The 12SI-R-( -)DOI used in these experiments was generously provided by Dr. C. A. Mathis (Lawrence Berkeley Laboratory); the radiosynthesis and procedures for determining the specific activity of this radioligand have been described elsewhere . For saturation experiments, 1251-R-(-)DOI was diluted 1: 10 with cold carrier R-(-)DOI. Saturation binding was determined in triplicate over a concentration range of 0.025-5.5 nM for both 'ZSI-R-(-)DOl and 3H-ketanserin. Nonspecific binding was defined for 1251-R-(-)DOI as the excess over blanks taken in the presence of lo-' M 5-HT, while for 'Hketanserin, 1O-6 M cinanserin was used to define nonspecific binding. Drugs were dissolved in buffer, except for (+)butaclamol, which was dissolved to 10-l M in ethanol and then diluted in buffer. Following incubation at 25°C for 30 min, the assay mixtures were rapidly filtered through #32 glass fiber filters (Schleicher and Schuell, Keene, NH) and washed twice with 5 ml of 50 mM Tris-HCI buffer. Radioactivity for 3H-ketanserin binding was measured by liquid scintillation spectroscopy pattern is observed with lZSI-R-( -)DOI binding in bovine cortical membranes. In this tissue, saturable, specific binding of 1251-R-(-)DOI cannot be detected (Fig. 1B) . Specific binding represents less than 20% of total binding at IZ51-R-( -)DOI concentrations above 0.6 nM. Statistically significant specific 1251-R-(-)DOI binding cannot be detected in the bovine cortex at radioligand concentrations above 4 nM, where specific binding represents only 8 f 1% of total radioligand binding (n = 3). The Scatchard plots of these data, analyzed according to the method of Rosenthal (1967) , are shown in Figure 2A . In rat cortical membranes, Scatchard analysis of the saturation data indicates a KD of 0.63 nM for 1Z51-R-(-)DOI with a B,,, value of2.5 + 0.2 pmol/gm tissue. The binding data for L251-R-(-)DOI in bovine cortex cannot be analyzed using the Scatchard transformation due to the extremely low level of specific binding, relative to total binding, that is detected in this tissue. A summary of all saturation experiments is provided in Table 1 . By contrast, specific and saturable 3H-ketanserin binding can be detected in both rat and bovine brain membranes (Fig. 2B ).
In rat cortical membranes, 3H-ketanserin displays an apparent KD of 1.0 + 0.1 nM and a B,,,,, of 11 * 0.4 pmol/gm tissue (Table 1) . In bovine cortex, 3H-ketanserin displays an apparent 
Species distribution of lZ51-R-(--)DOI binding sites
Radioligand binding studies were performed with lz51-R-( -)DOI using tissues from a variety of species. As shown in Table 2 , considerable variation exists in the amount of specific 125I-R-(-)DOI binding using 0.1 nM radioligand in various mammalian species. Specific binding ranged from more than 100% of the amount observed in rat cortex (i.e., mouse and dog) to less than 30% (i.e., bovine cortex). The phylogenetic and/or functional significance of the species variations is unclear at the present time.
Drug competition studies with lZ51-R-(-)DOI-and 3H-ketanserin-labeled binding sites in rat and bovine cortex Drug competition studies were performed using lz51-R-( -)DOI in rat cortex and 3H-ketanserin in bovine cortex (Table 3) . 5-HT is the most selective agent in terms of its relative affinity for the 2 sites. In the rat cortex, 5-HT displays a K, value of 3.0 f 0.7 nM and a Hill slope of approximately unity. Using jH-ketanserin as the radiolabel in rat cortex, the competition curve produced by 5-HT is relatively shallow, with a Hill slope of 0.67. A third pattern of 5-HT competition is observed when 3H-ketanserin is used in bovine cortex. 5-HT appears to be least potent under this condition, with lo-' M 5-HT displacing only 20-30% of specific 3H-ketanserin binding. The apparent K, value of 5-HT versus 3H-ketanserin in bovine cortex is 750 f 50 nM. Importantly, the Hill slope of 5-HT versus 3H-ketanserin binding in the bovine cortex is 0.96. Therefore, 5-HT displays approximately 250-fold higher potency for 1251-R-(-)DOI-labeled sites than for 3H-ketanserin-labeled sites (Table 3, Fig. 3) .
The most potent competitors for the sites labeled by lZ51-R-(-)DOI are phenylalkylamines, i.e., 4-substituted 2,5-dimethoxyphenylisopropylamines such as (-)DOB, (-)DOM, and (-)DOI itself. These agents display subnanomolar affinity for specific IZ51-R-(-)DOI binding (Table 3) . By contrast, these agents are approximately loo-fold less potent in displacing specific 3H-ketanserin binding in bovine cortex. Indeed, most drugs examined in the competition studies are more potent at 125I-R- 250  150  150  130  130  130  130  120  110  100  93  90  83  68  63  46  46  38  13  8  3  3 Radioligand binding assays were performed as described in Materials and Methods. IC,, values were determined by loglogit analysis. K, values were calculated from the formula K, = IC,dl + [4/K, where KD for '251-R-(-)DOI was 0.63 nM and [fl ranged from 0.02 to 0.1 nM. The K, for 'H-ketanserin was 1.2 nM and [fl ranged from 0.1 to 0.2 nM. Values given are the means k SE of 3-6 experiments, each performed in triplicate.
jr)DOI-labeled sites than at 3H-ketanserin-labeled sites (Table   Multiple 5 -HT, antagonists display nanomolar affinity for both 1251-R( -)DOI-and )H-ketanserin-labeled sites (Table 3) . Both LSD and spiperone, for example, display approximately equal affinity for both sites. Ketanserin is also equipotent at the 2 sites, a finding consistent with its apparent ability to label 2 distinct recognition sites. No agents were identified which displayed more than an order of magnitude higher affinity for 3H-ketanserin-labeled sites compared with 12SI-R(-)DOI-labeled sites.
Correlation of '2SI-R-(-)DOI-labeled sites with drug afinities for 5-HT receptor subtypes tories. As expected on the basis of their structural similarity, a highly significant correlation is found between drug affinities for sites labeled by 1251-R-(-)DOI with drug affinities for sites labeled by 77Br-R-(-)DOB ( Fig. 4A ; r = 0.93, p < 0.01; n = 26). A lower, but still significant, correlation is found between drug affinities for 1251-R-(-)DOI-labeled sites in rat cortex and 'Hketanserin-labeled sites in bovine cortex ( Fig. 4B ; r = 0.63, p < 0.01; n = 30). A significant correlation is also found between drug affinities for 1251-R-(-)DOI sites and 5-HT,, sites ( Fig. 4C ; r = 0.78, p < 0.01; n = 2 1) characterized by other investigators. Therefore, these data are consistent with an identity between sites labeled by 1251-R(-)DOI and 3H-(+)DOB or "Br-R-(-)DOB and a similarity between lZ51-R-( -)DOI-labeled sites and putative 5-HT,,-or 5-HT,,-binding sites. Drug affinities for 1251-R-( -)DOI-labeled sites in rat cortex were As shown in Figure 5 , no significant correlations could be compared with drug affinities for 77Br-R-( -)DOB-labeled sites detected between drug affinities for 12SI-R-(-)DOI-labeled sites determined previously Correlation between drug afinities for 12SI-R-(-)DOI-labeled sites and human hallucinogenic doses Drug affinities for 12SI-R-(-)DOI-labeled sites were correlated with human hallucinogenic doses as reported in Shulgin (1978) and Glennon and Rosecrans (1982) . A highly significant correlation was found ( Fig. 6 ; r = 0.86, p < 0.01; n = 14). Thirteen of the 14 drugs analyzed lie close to the linear-regression line. The single exception is d-LSD, which has significantly lower affinity for 1251-R-(-)DOI sites than might be expected on the basis of its human hallucinogenic potency. These data suggest that the sites labeled by 1251-R-(-)DOI may play a role in the pathophysiology of hallucinosis.
Discussion
The major finding of the present study is that 1251-R-(-)DOI labels a saturable, high-affinity population of specific binding sites in rat cortex that are similar, but not identical, to binding sites labeled by 3H-ketanserin in bovine cortex and to S-HT,, binding sites. In the rat cortex, these sites constitute approximately 20% of the total binding site density labeled by 'Hketanserin in the same tissue. In bovine cortex, however, a specific, saturable, high-affinity recognition site for IZ51-R-( -)DOI cannot be detected. These data indicate that lZ51-R-( -)DOI specifically labels a S-HT recognition site in rat cortex that does not exist, or cannot be detected due to its low density, in bovine brain. These data also support the recent observations of Pierce and Peroutka (1989) using jH-( &)-DOB in both rat and bovine brain.
The present study provides radioligand binding evidence for the existence of distinct 5-HT,-recognition sites in brain membranes. Furthermore, the presence of these putative 5-HT, binding site subtypes appears to vary in different mammalian species.
In accordance with accepted nomenclature, we propose that the high-affinity site labeled by 125I-R-( -)DOI, 3H-( &)-DOB, and "Br-R-(-)DOB be designated 5-HT,, membrane recognition sites. 3H-Ketanserin labels both these putative 5-HT,, sites as well as a subpopulation of 5-HT, recognition sites in bovine brain, which we suggest be designated as 5-HT,, binding sites.
The results of our competition experiments using lZ51-R-
(-)DOI in rat cortex and 3H-ketanserin in bovine cortex also support the hypothesis of 5-HT, binding site heterogeneity. 5-HT is the most "selective" agent that can be used to discriminate the 2 sites (Table 3) . Specifically, 5-HT displays nanomolar affinity for 1*51-R-(-)DOI-labeled sites (K, = 3.0 f 0.7 nM), while it displays 250-fold weaker affinity for the sites labeled by 3H-ketanserin (K, = 750 f 50 nM). The 4-substituted, 2,5-dimethoxyphenylisopropylamines also discriminate between the 2 sites. Each of these agents shows an approximately loo-fold higher affinity for the 5-HT,, sites labeled by 1251-R-(-)DOI than for the 5-HT,, sites labeled by 3H-ketanserin (Table 3) . By contrast, 5-HT, antagonists show equal affinity for both sites or slightly higher affinity for the 5-HT,, site (Table 3) . Correlation analyses of drug affinities also support the interpretation that lZ51-R-( -)DOI in rat cortex and 3H-ketanserin in bovine cortex are labeling different populations of binding sites (Figs. 4, 5 ). There is a highly significant correlation between drug affinities for the lz51-R-( -)DOI site and the site labeled by "Br-R-(-)DOB (r = 0.93, p < 0.01) strongly suggesting that these radioligands are labeling the same membrane recognition sites (Fig. 4A) . However, there is also a significant but lower correlation between drug affinities for the 1251-R-(-)DOI site and the )H-ketanserin labeled site in bovine cortex ( Fig. 4B ; r = 0.68, p < 0.01). These observations suggest that the "5-HT2" binding site labeled by 3H-ketanserin is similar but not identical to the site labeled by 12SI-R-(-)DOI and "Br-R-(-)DOB. Indeed, most previous studies have been primarily directed at the 5-HT,, receptor while tending to overlook the 5-HT,, receptor. This is not surprising in view of the fact that the 5-HT,, binding component comprises only 15-20% of the total "5-HT," binding, as measured using 3H-ketanserin in rat cortex.
A significant correlation also exists between drug affinities for the '*51-R-(-)DOI binding site and the 5-HT,, recognition site, as characterized by other investigators (Fig. 4C) . This observation provides further evidence for the similarities between the 5-HT,, recognition site and the 5-HT, receptor "family." Hoyer (1988) has commented on the pharmacological and biochemical similarities between the 5-HT,, and 5-HT, receptors and has suggested that the 5-HT,, receptors should be more appropriately classified as a 5-HT, receptor subtype. Our data agree with this suggestion. Table 3 and correlated with drug affinities for A, "Br-R-( -)DOB-labeled sites ; B, 'H-ketanserinlabeled sites in bovine cortex (Table 3) ; and C, 5-HT,, binding sites (Pazos et al., 1984; Hoyer et al., 1985; Peroutka, 1986; Titeler et al., 1988) . Table 3 and correlated with drug affinities for A, 5-HT,, binding sites (Hoyer et al., 1985; Peroutka, 1986; Titeler et al., 1988) ; B, 5-HT,, binding sites (Hoyer et al., 1985; Peroutka, 1986; Titeler et al., 1988) ; C, 5-HT,, binding sites Herrick-Davis et al., 1988) ; and D, 5-HT, binding sites (Hoyer and Neijt, 1988; . Figure 6 . Correlation of drug affinities for 125I-R-( -)DOI-labeled sites in rat cortex with human hallucinogenic doses. Drug affinities for 1251-R-(-)DOI were obtained from Table 3 and correlated with human hallucinogenic drug dosages as reported by Shulgin (1978) and Glennon and Rosecrans ( 1982) .
Alternatively, the apparent differences between lZSI-R-(-)DOI binding and 3H-ketanserin binding could be due to the ability of Y-R-( -)DOI to label 5-HT,, sites as well as 5-HT, sites in the rat cortex. Indeed, McKenna et al. (1989a) showed that 12SI-R-(-)DOI does label 5-HT,, sites in the rat choroid plexus. However, Hoyer (1988) has shown that 5-HT,, receptors are absent or only minimally present in rat cortex. Since all of the studies in the present report were performed in rat cortex, it is unlikely that 5-HT,, binding accounts for a significant portion of the binding sites analyzed. This conclusion is further confirmed by the lack of identity between drug affinities for lZSI-R-(-)DOI binding sites and 5-HT,, sites (see Fig. 413 These data are consistent with the extensive observations of Titeler and colleagues Titeler et al., 1985 Titeler et al., , 1987 Lyon et al., 1987; Glennon et al., 1988) . These investigators proposed that the agonist radioligand 'H-( *)DOB labels a "high-affinity agonist state" of the 5-HT, receptor that represents receptor/N subunit complexes, while antagonist radioligands such as 3H-ketanserin label both free receptors and receptor/N subunit complexes. This hypothesis derived, in large part, from the observation that drugs such as 5-HT and the phenylisopropylamines display low Hill slopes against jH-ketanserin binding in rat cortex. However, if the "SHT," receptor in bovine and rat brain were identical, then similar experimental results would be expected in both tissues. The present data are clearly inconsistent with this hypothesis. Alternatively, we suggest that the site labeled by 1251-R-(-)DOI (the putative SHT,, binding site) is a distinct molecular entity and not a high-affinity agonist "state" of the S-HT, receptor.
Conceivably, our failure to detect a "high-affinity agonist state" of the SHT, receptor in bovine cortex results from a differential lability of the G-protein associated with the receptor in rat versus bovine brain. For example, differences in the processing of the 2 different tissues (freezing, thawing, etc.) may result in the inability to generate the "high-affinity agonist state" in bovine, as opposed to rat, tissues. This possibility appears unlikely, however, as both rat and bovine tissues were stored under identical conditions and were processed and studied on the same day using identical experimental procedures.
Another important observation is that, in general, 5-HT agonists display higher affinities for the putative 5-HT,, site labeled by 1*51-R-(-)DOI than for the 5-HT,, site labeled by 3H-ketanserin. This finding may be viewed as providing general support for the hypothesis that 1251-R-(-)DOI labels a "highaffinity agonist state" of the 5-HT, receptor. Therefore, a clear need exists to develop antagonists that preferentially interact with 12SI-R-(-)DOI binding sites in order to provide further support for our hypothesis of 2 distinct 5-HT, binding site subtypes. Until such agents become available, we do not believe that the "high affinity agonist state" hypothesis of Titeler and colleagues should be completely discarded.
Finally, the structural similarities of DOB and its iodinated congener, DOI, and their similar pharmacological action as human hallucinogens, suggest that both agents interact with identical receptors. The high affinity of many hallucinogens for 5-HT,, receptors (Table 3 ) and the significant correlation that exists between these affinities and human hallucinogenic doses (Fig. 6) indicate that this receptor subtype may play a role in hallucinosis. Future studies are likely to further define the functional and clinical relevance of the 5-HT,, binding site and should facilitate the understanding of 5-HT in both normal and abnormal brain function.
